Insulin-like growth factor 1 receptor expression in advanced non-small-cell lung cancer and its impact on overall survival

Author:

Humar Mojca1,Kern Izidor2,Vlacic Gregor2,Hadzic Vedran3,Cufer Tanja2

Affiliation:

1. General hospital of Nova Gorica , Ulica padlih borcev 13a, 5290 Šempeter Pri Gorici , Slovenia

2. University Clinic Golnik , Golnik , Slovenia

3. Faculty of Sport , University of Ljubljana , Slovenia, Ljubljana , Slovenia

Abstract

Abstract Background The insulin-like growth factor 1 receptor (IGF1R) expression has been addressed as a potential prognostic marker in non-small-cell lung cancer (NSCLC) in various studies; however, the associations between IGF1R expression and prognosis of advanced NSCLC patients is still controversial. The aim of our observational, cohort study was to evaluate the expression of IGF1R in advanced NSCLC and its prognostic role. A subgroup analysis was performed to address the influence of pre-existing type 2 diabetes mellitus (T2DM) status on IGF1R expression and overall survival (OS). Patients and methods IGF1R expression was evaluated in 167 consecutive advanced NSCLC patients (stage IIIB and IV), diagnosed and treated at one university institution, between 2005 and 2010. All patients received at least one line of standard cytotoxic therapy and 18 of them had pre-existing T2DM. IGF1R expression was determined by immunohistochemical (IHC) staining, with score ≥ 1+ considered as positive. Information on baseline characteristics, as well as patients’ follow-up data, were obtained from the hospital registry. Associations of IGF1R expression with clinical characteristics and overall survival were compared. Results IGF1R expression was positive in 79.6% of patients, significantly more often in squamous-cell carcinoma (SCC) compared to non-squamous-cell (NSCC) histology (88.7% vs. 74.3%; P = 0.03). IGF1R positivity did not correlate with T2DM status or with other clinical features (sex, smoking status, performance status). Median OS was similar between IGF1R positive and IGF1R negative group (10.2 vs. 8.5 months, P = 0.168) and between patients with or without T2DM (8.7 vs. 9.8 months, P = 0.575). Neither IGF1R expression nor T2DM were significant predictors of OS. Conclusions IGF1R or T2DM status were not significantly prognostic in described above collective of advanced NSCLC treated with at least one line of chemotherapy. In addition, no association between T2DM status and IGF1R expression was found. Further studies on IGF1R expression and its prognostic as well as therapeutic consequences in a larger collective of advanced NSCLC patients, with or without T2DM, are needed.

Publisher

Walter de Gruyter GmbH

Subject

Radiology Nuclear Medicine and imaging,Oncology

Reference66 articles.

1. International Agency for Research on Cancer. World health Organization. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 20012. Lung cancer fact sheet. [Citated 2016 Jun 15]. Available at http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx?cancer=lung.

2. Morgensztern D, Ng SH, Gao F, Govindan R. Trends in stage distribution for patients with non-small cell lung cancer: A National Cancer Database survey. J Thorac Oncol 2010; 5: 29-33. 10.1097/JTO.0b013e3181c5920c

3. Debevec L, Jerič T, Kovač V, Bitenc M, Sok M. Is there any progress in routine management of lung cancer patients? A comparative analysis of an institution in 1996 and 2006. Radiol Oncol 2009; 43: 47-53. 10.2478/v10019-009-0008-x

4. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, et al.SEER cancer statistics review, 1975-2013. Bethesda: National Cancer Institute. [Citated 2016 Sept 04]. Available at http://seer.cancer.gov/csr/1975_2013/

5. Sechler M, Cizmic AD, Avasarala S, Van Scoyk M, Brzezinski C, Kelley N, et al. Non-small-cell lung cancer: molecular targeted therapy and personalized medicine – drug resistance, mechanisms, and strategies. Pharmgenomics Pers Med 2013; 6: 25-36. 10.2147/PGPM.S26058

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3